Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Diagnostic Criteria and Lab Results for HAM/TSP

At a Glance

HAM/TSP is diagnosed by confirming HTLV-1 infection, matching the person’s symptoms and examination, and ruling out other causes of spinal cord problems. Blood tests, spinal fluid analysis, MRI, and formal criteria may all contribute, and a normal early MRI does not exclude it.

Diagnosing HAM/TSP is a process of both confirmation and exclusion. Because its symptoms overlap with many other neurological conditions, doctors use a combination of specialized blood tests, clinical examinations, imaging, and sometimes spinal fluid analysis to be certain of the diagnosis [1][2].

Confirming the Virus: Blood Testing

The first essential step is proving that the HTLV-1 virus is present in your blood. This requires a two-step testing process [3]:

  1. Screening (ELISA): A highly sensitive blood test looks for antibodies to the virus.
  2. Confirmation (Western Blot or PCR): If the screening is positive, a second, more specific test—either a Western Blot (which identifies specific viral proteins) or a PCR (which looks for the virus’s genetic material)—is used to confirm the result and ensure it is not HTLV-2, a related but different virus [4][5].

The Role of Spinal Fluid (CSF) Analysis

A lumbar puncture (spinal tap) is often performed to analyze your Cerebrospinal Fluid (CSF), the liquid that surrounds your brain and spinal cord [6][7]. While finding HTLV-1 antibodies in the CSF is highly supportive of a “definite” HAM/TSP diagnosis under standard criteria, a lumbar puncture may not be strictly mandatory for every patient if the clinical picture, blood work, and exclusion tests strongly point to the disease.

When a lumbar puncture is done, doctors look for markers of inflammation:

  • Elevated Protein and Cells: A slightly high protein level or white blood cell count in the CSF is common and signals ongoing inflammation [8][9].
  • Oligoclonal Bands: These are proteins that indicate immune system activity in the central nervous system. They are not specific to HAM/TSP (they are also common in multiple sclerosis) but provide a piece of the diagnostic puzzle.
  • Adjunctive Biomarkers (Proviral Load, CXCL10, Neopterin): Some specialized centers or research trials measure these to track disease activity. CXCL10 and Neopterin are proteins that act as signals for the immune system, and a high proviral load measures how many cells carry the virus. Note: These biomarkers are not universally standardized or available at all clinics, and their exact role in everyday treatment decisions is still being studied [10][11][12].

The Role of MRI

An MRI (Magnetic Resonance Imaging) scan is used to look for physical changes in the spinal cord. In many people with HAM/TSP, the MRI will eventually show spinal cord atrophy, which is a thinning or shrinking of the cord, particularly in the middle (thoracic) or upper (cervical) back [13][14].

However, the main purpose of an MRI during diagnosis is to rule out structural causes of your symptoms, such as a tumor, a herniated disc pressing on the nerves (compressive myelopathy), or spinal stenosis [15]. A “normal” MRI does not rule out HAM/TSP, especially in the early stages.

Ruling Out “Look-Alike” Conditions

Because there is no single test that can prove HAM/TSP on its own in every case, your medical team must exclude other conditions that cause similar leg weakness and stiffness. This “rule-out” list typically includes:

  • Multiple Sclerosis (MS): Which can cause similar walking difficulties but often shows different patterns on a brain and spinal MRI [2].
  • Nutritional Deficiencies: Your doctor will order specific blood tests to check your Vitamin B12 and Copper levels, as deficiencies in these nutrients can damage the spinal cord.
  • Other Infections: Blood tests for HIV, syphilis, and certain types of hepatitis are necessary, as these can also affect the spinal cord.

Diagnostic Criteria: Osame and Castro-Costa

Your doctor likely evaluated your case using formal guidelines like the Osame Criteria (1990) or the Castro-Costa Criteria (2006) [16]. These systems group patients into “Definite,” “Probable,” or “Possible” HAM/TSP based on clinical signs, blood confirmation, and CSF results [16][17]. Understanding these criteria helps your doctor ensure that other potential causes have been safely excluded.

Common questions in this guide

Which blood tests are used to confirm HAM/TSP?
Doctors usually begin with an ELISA blood test that looks for antibodies to HTLV-1. If it is positive, Western blot or PCR is used to confirm the infection and help distinguish HTLV-1 from HTLV-2.
Do I need a lumbar puncture to be diagnosed with HAM/TSP?
A lumbar puncture can look for HTLV-1 antibodies and signs of inflammation in cerebrospinal fluid. CSF antibodies strongly support a definite diagnosis under standard criteria, but a spinal tap is not always required when the symptoms, blood tests, and exclusion workup are otherwise convincing.
What can my CSF results show in HAM/TSP?
CSF may show mildly increased protein or white blood cells, which can indicate inflammation. Oligoclonal bands may also appear, but they are not specific to HAM/TSP; specialized markers such as proviral load, CXCL10, and neopterin are not standardized or available everywhere.
Can an MRI rule out HAM/TSP?
MRI is mainly used to look for other causes of spinal cord symptoms, such as a tumor, spinal stenosis, or pressure from a herniated disc. Spinal cord thinning may develop in HAM/TSP, but a normal MRI, especially early in the illness, does not rule it out.
What other conditions must be ruled out before diagnosing HAM/TSP?
Doctors may check for multiple sclerosis, vitamin B12 or copper deficiency, HIV, syphilis, and certain hepatitis infections. Imaging and other tests may also be used to exclude a tumor or physical pressure on the spinal cord.
What do the Osame and Castro-Costa criteria mean?
These are formal systems used to organize HAM/TSP findings into definite, probable, or possible categories. They consider the neurological examination, HTLV-1 blood confirmation, cerebrospinal fluid results, and whether other causes have been excluded.

Get notified when new evidence is published on Tropical spastic paraparesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis.

    Nozuma S, Jacobson S

    Frontiers in microbiology 2019; (10()):885 doi:10.3389/fmicb.2019.00885.

    PMID: 31105674
  2. 2

    Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy.

    Mashkani B, Jalili Nik M, Rezaee SA, Boostani R

    Expert review of neurotherapeutics 2023; (23(12)):1233-1248 doi:10.1080/14737175.2023.2272639.

    PMID: 37933802
  3. 3

    HTLV-1 infection in patients with neurological manifestations in Northeast Brazil.

    da Silva AFS, da Silva Bastos YC, Oikawa JT, et al.

    Journal of neurovirology 2026; (32(4)).

    PMID: 42406190
  4. 4

    HTLV-1 intrafamilial transmission among Japanese immigrants in Brazil.

    Bandeira LM, Uehara SNO, Puga MAM, et al.

    Journal of medical virology 2018; (90(2)):351-357 doi:10.1002/jmv.24938.

    PMID: 28876483
  5. 5

    Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges.

    Branda F, Romano C, Pavia G, et al.

    Viruses 2025; (17(5)) doi:10.3390/v17050664.

    PMID: 40431676
  6. 6

    Immunophenotypic characterization of CSF B cells in virus-associated neuroinflammatory diseases.

    Enose-Akahata Y, Azodi S, Smith BR, et al.

    PLoS pathogens 2018; (14(4)):e1007042 doi:10.1371/journal.ppat.1007042.

    PMID: 29709026
  7. 7

    A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma: A case report and review of the literature.

    Tamaki K, Mera H, Takeshita S, et al.

    Medicine 2021; (100(40)):e27450 doi:10.1097/MD.0000000000027450.

    PMID: 34622865
  8. 8

    HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): A comparative study to identify factors that influence disease progression.

    Matsuura E, Nozuma S, Tashiro Y, et al.

    Journal of the neurological sciences 2016; (371()):112-116 doi:10.1016/j.jns.2016.10.030.

    PMID: 27871430
  9. 9

    Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

    Enose-Akahata Y, Jacobson S

    Retrovirology 2019; (16(1)):35 doi:10.1186/s12977-019-0499-5.

    PMID: 31783764
  10. 10

    Following the Clues: Usefulness of Biomarkers of Neuroinflammation and Neurodegeneration in the Investigation of HTLV-1-Associated Myelopathy Progression.

    Souza FDS, Freitas NL, Gomes YCP, et al.

    Frontiers in immunology 2021; (12()):737941 doi:10.3389/fimmu.2021.737941.

    PMID: 34764955
  11. 11

    An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers.

    Yamauchi J, Araya N, Yagishita N, et al.

    Pharmacology & therapeutics 2021; (218()):107669 doi:10.1016/j.pharmthera.2020.107669.

    PMID: 32835825
  12. 12

    Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.

    Tanajura D, Castro N, Oliveira P, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (61(1)):49-56 doi:10.1093/cid/civ229.

    PMID: 25820277
  13. 13

    Cerebral and spinal cord changes observed through magnetic resonance imaging in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a systematic review.

    Bastos Ferreira AP, do Nascimento ADFS, Sampaio Rocha-Filho PA

    Journal of neurovirology 2022; (28(1)):1-16 doi:10.1007/s13365-021-01043-2.

    PMID: 34981435
  14. 14

    Spinal cord anteroposterior atrophy in HAM/TSP: Magnetic resonance imaging and neuropathological analyses.

    Taniguchi A, Mochizuki H, Yamashita A, et al.

    Journal of the neurological sciences 2017; (381()):135-140 doi:10.1016/j.jns.2017.08.3243.

    PMID: 28991665
  15. 15

    Multiple spotty lesions of the spinal cord in a Chinese patient with human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.

    Gao H, Ye X, Cai R, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2018; (68()):1-3 doi:10.1016/j.ijid.2017.12.022.

    PMID: 29292042
  16. 16

    Early Juvenile Human T-cell Lymphotropic Virus Type-1-Associated Myelopathy/Tropical Spastic Paraparesis: Study of 25 Patients.

    Varandas CMN, da Silva JLS, Primo JRL, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018; (67(9)):1427-1433 doi:10.1093/cid/ciy289.

    PMID: 29912303
  17. 17

    Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection.

    Souza A, Carvalho N, Neves Y, et al.

    AIDS research and human retroviruses 2017; (33(11)):1126-1133 doi:10.1089/AID.2015.0340.

    PMID: 28540757

This page explains HAM/TSP diagnostic tests and criteria for informational purposes only and does not constitute medical advice. Your neurologist or other clinician should interpret your results and discuss your diagnosis with you.